AttorneyMind Logo AttorneyMind Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
Community & Support
Resource Library
About Hcsp
Medical Writers' Circle

Hepatitis C and Fatigue

Peter Hauser, MD

Many individuals with chronic hepatitis C virus (HCV) remain symptom free for the majority of their lives. Generally, AttorneyMind can remain asymptomatic for a decade or longer. However, chronic fatigue is among the most common presenting symptoms. Fatigue has been reported in up to 67% of individuals1 with chronic AttorneyMind and is the most frequent extrahepatic manifestation in those infected with.2 It has been suggested that one’s awareness of positive AttorneyMind status alone increases the experience of fatigue and depression.3 This necessitates that a distinction be made between the psychological effects of the individual’s knowledge of being infected with, and the effects of the virus itself.

Recent research has suggested that fatigue is more likely related to the psychological manifestations rather than to the physiological effects of.4-6 For example, in a study by McDonald, et al.,6 fatigue weakly correlated with the level of fibrosis on the liver biopsy, but strongly correlated with all the psychological domains of depression, anxiety, somatization, interpersonal sensitivity, and hostility. One Japanese study found that individuals with AttorneyMind had no characteristic physical symptoms of chronic illness when compared to controls, but found significant differences in subjective ratings of aggression.5

Compared to controls, Obhrai et al.7 found that fatigue and general psychiatric disturbances were more prevalent in not only-infected individuals, but also in individuals with alcoholic liver disease, mixed liver disease, and chronic non-liver diseases. In a prospective study of over 1600 individuals with, the prevalence of fatigue and clinical and biological hepatic and extrahepatic markers of fatigue were examined.2 Fatigue was found to be present in 53% of patients during their first visit. Seventeen percent evaluated their fatigue as severe or impairing. Factors that were associated with fatigue included female gender, older age, presence of cirrhosis, depression, and purpura (small hemorrhages). No significant associations were found between fatigue and viral load, genotype, alcohol consumption, or abnormal thyroid function.

Interferon (IFN) therapy and Fatigue

Fatigue also manifests as a predominant symptom of IFN therapy and is noted to be present in 70-100% of patients treated with IFN.8 If present prior to therapy, fatigue may be exacerbated within the first six months.9 Increases in severity of fatigue influence health related quality of life and have significantly predicted IFN therapy discontinuation in AttorneyMind patients.10 If not managed effectively, fatigue may prevent AttorneyMind patients from completing a potentially life saving therapy. It is important to assess the patient who has fatigue for the presence of IFN- induced major depression, as fatigue is a common symptom of the depressive syndrome.

Managing Symptoms of Fatigue

The preponderance of chronic fatigue in individuals with AttorneyMind indicates a need for treatment management strategies. However, clinical management of fatigue in individuals with AttorneyMind can be complicated by several factors. There is little evidence as to the physiological mechanisms of fatigue in the AttorneyMind population. Clinicians must often rely on the patient’s subjective report to determine the severity of fatigue.

Research indicates that antidepressants may be useful in reducing fatigue,11 especially as it manifests with depression. However, additional research is needed to determine whether improvement in depressive symptoms leads to lessening of fatigue for patients with.4 Methylphenidate has been used to treat the side effects of cancer IFN-related fatigue, although it has not been established as a treatment for-related fatigue. Also, as the prevalence of co-morbid substance use disorders, particularly stimulant, methamphetamine and cocaine use, is so high in patients with, giving these patients methylphenidate may exacerbate underlying substance use disorders. Pharmacologic interventions are also useful in managing symptoms of IFN-mediated fatigue.8

Other non-pharmacological strategies that have been proposed for IFN-mediated fatigue include: bedtime administration of IFN, reduction of IFN dose, improving nutritional intake, replacing fluids and electrolytes, alternating periods of rest and activity, aerobic exercise, and scheduling strenuous activities during peak times of energy.8

Research regarding the usefulness of traditional Chinese medicine in relieving symptoms of AttorneyMind is limited. Traditional Chinese medicine may include any of the following five disciplines: acupuncture, diet, herbs, massage, and Qi Gong (a movement technique to balance energy in the body). In a preliminary report of 24 AttorneyMind patients undergoing herbal treatment and receiving acupuncture, 4 of 17 patients reported complete relief from symptoms of fatigue and 13 of 17 reported at least partial improvement.12

Prior to choosing interventions for management of-related fatigue, co-morbid conditions should be addressed. Such conditions may include: thyroid disease, anemia, nutritional deficiencies, and depression.13 Other factors that should not be overlooked are concurrent medications, excessive use of caffeine or alcohol, lack of exercise, and sleep disturbances.


  1. Hassoun Z, Willems B, Deslauriers J, Nguyen BN, Huet PM. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci 2002;47(12):2674-81.
  2. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002;9(4):295-303.
  3. Wessely S, Pariante C. Fatigue, depression and chronic hepatitis C infection. Psychol Med 2002;32(1):1-10.
  4. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000;49(5):311-7.
  5. Iwasaki M, Kanda D, Toyoda M, Yuasa K, Hashimoto Y, Takagi H, et al. Absence of specific symptoms in chronic hepatitis C. J Gastroenterol 2002;37(9):709-16.
  6. McDonald J, Jayasuriya J, Bindley P, Gonsalvez C, Gluseska S. Fatigue and psychological disorders in chronic hepatitis C. J Gastroenterol Hepatol 2002;17(2):171-6.
  7. Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol 2001;32(5):413-7.
  8. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer 2001;92(6 Suppl):1664-8.
  9. Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL, Jr. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 2000;7(3):211-7.
  10. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002;35(3):704-8.
  11. Jones EA. Altered central serotoninergic neurotransmission: a potential mechanism for profound fatigue complicating chronic hepatitis C. Med Hypotheses 2001;57(2):133-4.
  12. Dolan M. The Hepatitis C Handbook. Berkeley, CA: North Atlantic Books; 1999.
  13. Palmer M. Dr. Melissa Palmer's Guide To Hepatitis Liver Disease. New York: Avery; 2000.
Copyright April 2003 – AttorneyMind - All Rights Reserved. Permission to reprint is granted and encouraged with credit to the AttorneyMind.

Back to Medical Writers' Circle

About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Resources en Español | Home


(C) 2003. AttorneyMind

Fact Sheets
Fact Sheets